RNAseq changes in pre MAPKi treatment and post MAPKi resistance Melanomas
Melanoma resistance to MAPK- or T cell checkpoint-targeted therapies represents a major clinical challenge, and treatment failures of MAPK-targeted therapies due to acquired resistance often require salvage immunotherapies. We show that genomic analysis of acquired resistance to MAPK inhibitors revealed key driver genes but failedto adequately account for clinical resistance. From a large-scale comparative analysis of temporal transcriptomes from patient-matched tumor biopsies, we discovered hig...
Provenance — who produced it, who reused it
Linked to 17 papers in the literature. Roles are inferred factual signals (who deposited the data vs who reused it), with counts — never a judgement about any author.
- Targeting mitochondrial biogenesis to overcome drug resistance t... 2016 · 299 cites
- Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark... 2020 · 154 cites
- Oncogenic PI3K/AKT promotes the step-wise evolution of combinati... 2018 · 106 cites
- Sustained activation of the Aryl hydrocarbon Receptor transcript... 2018 · 95 cites
- Deep generative neural network for accurate drug response imputa... 2021 · 90 cites
- Genomic hallmarks and therapeutic implications of G0 cell cycle... 2023 · 74 cites
11 further papers cite this accession but reuse could not be confirmed.
Deep data QC
metadata only · no data-level QC for this typeStandardized, field-standard QC computed by touching the data — every metric states how it was obtained
No quantitative QC rubric exists for this data type yet, so it is deliberately left unscored — this is an honest "not applicable", not a poor rating.
measured = computed from the data · extrapolated/reported = derived or from the repository · dq-1.0 · provisional — verify independently